We are currently faced with a global pandemic while at the same time faced with volatile oil prices. Many companies and industries will need a life-line to continue to stay in business. Management will face pressure from government officials with respect to capital allocation and share repurchases. Valuation has become virtually impossible for analysts as earnings are very difficult to predict.
I present Zynex (ZYXI), a high-growth company with no debt, in a somewhat insulated niche of pain management. I'll provide a little background as Zynex has been covered before on Seeking Alpha.